Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

ClinicalTrials.gov ID: NCT05468489

Public ClinicalTrials.gov record NCT05468489. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 29, 2026, 9:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)

Study identification

NCT ID
NCT05468489
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Shanghai Henlius Biotech
Industry
Enrollment
200 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 17, 2022
Primary completion
Feb 27, 2026
Completion
Dec 30, 2027
Last update posted
Oct 20, 2025

2022 – 2027

United States locations

U.S. sites
67
U.S. states
30
U.S. cities
64
Facility City State ZIP Site status
Alabama Oncology Birmingham Alabama 35223 —
City of Hope - Phoenix Goodyear Arizona 85338 —
Arizona Clinical Research Center (ACRC) Tucson Arizona 85715 —
Highlands Oncology Group Springdale Arkansas 72762 —
Compassionate Care Research Group Fountain Valley California 92708 —
Providence Medical Foundation Fullerton California 92835 —
Los Angeles Cancer Network Glendale California 91204 —
OPN - Oncology Physician Network Los Alamitos California 90720 —
Kaiser Permanente Research (Southern California) Los Angeles California 90034 —
UC Davis Sacramento California 95817 —
UCHealth Memorial Hospital North Colorado Springs Colorado 80920 —
Banner MD Anderson Cancer Center (BMDACC) Greeley Colorado 80631 —
MD Anderson- North Colorado Medical Center Greeley Colorado 80631 —
Advanced Cancer Treatment Centers Brooksville Florida 34613 —
Cancer Specialists North Florida Jacksonville Florida 32256 —
Mount Sinai Comprehensive Cancer Center Miami Florida 33140 —
Florida Cancer Affiliates- (Ocala Oncology - Main) Ocala Florida 34473 —
Mid Florida Hematology and Oncology Center Orange City Florida 32763 —
BRCR Global Plantation Florida 33322 —
Napa Research Pompano Beach Florida 33064 —
Advanced Research Tamarac Florida 33321 —
City of Hope- Chicago Chicago Illinois 60099 —
Cancer Center of Decatur Decatur Illinois 62526 —
Accellacare of Duly Tinley Park Illinois 60487 —
Northwest Cancer Centers Dyer Indiana 46311 —
Cancer Center of Kansas Wichita Kansas 67214 —
Baptist Health Lexington Lexington Kentucky 40503 —
Pikeville Hospital Pikeville Kentucky 41501 —
CHRISTUS St. Frances Cabrini Cancer Center Alexandria Louisiana 71301 —
Pontchartrain Cancer Center Hammond Louisiana 70433 —
Lahey Hospital & Medical Center Burlington Massachusetts 01805 —
Henry Ford Health Providence Southfield Hospital Southfield Michigan 48075 —
Health Partners Cancer Center at Regions Hospital Saint Paul Minnesota 55101 —
Hattiesburg Clinic Hematology/Oncology Hattiesburg Mississippi 39401 —
North Mississippi Medical Center Hematology and Oncology Clinic Tupelo Mississippi 38801 —
MidAmerica Division Inc., c/o Research Medical Center Kansas City Missouri 64132 —
Lake Regional Osage Beach Missouri 65065 —
St. Vincent Frontier Cancer Center Billings Montana 59102 —
University of Nebraska Medical Center Omaha Nebraska 68106 —
Renown Health Reno Nevada 89502 —
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03756 —
Regional Cancer Care Associates LLC RCCA Freehold New Jersey 03756 —
Jersey Shore University Medical Center Neptune City New Jersey 07753 —
Elmhurst (BRANY site) Elmhurst New York 11373 —
Northwell Health Lake Success New York 11042 —
Stony Brook Cancer Center Stony Brook New York 11794 —
Great Lakes Cancer Care (Kaleida Health) Williamsville New York 14221 —
Summa Health Akron Ohio 44304 —
Cleveland Clinic Mercy Hospital Canton Ohio 44708 —
Aultman Cancer Center Canton Ohio 44710 —
University Hospitals Cleveland Medical Center Cleveland Ohio 44106 —
Tricounty Hematology and Oncology Associates Massillon Ohio 44646 —
CharterCARE (Roger Williams) Providence Rhode Island 02908 —
Monument Health Rapid City South Dakota 57701 —
CHRISTUS Institute for Innovation & Advanced Clinical Care Corpus Christi Texas 78404 —
DHR Research Edinburg Texas 78539 —
Millennium Research and Clinical Development Houston Texas 77090 —
Lumi Research Kingwood Texas 77339 —
Joe Arrington Cancer Research and Treatment Center Lubbock Texas 79410 —
The University of Texas Health Science Center at Tyler/HOPE Cancer Center Tyler Texas 75701 —
Utah Cancer Specialists Salt Lake City Utah 84106 —
Huntsman Cancer Institute Salt Lake City Utah 84112 —
American Oncology Network Vista Oncology Division Olympia Washington 98502 —
Northwest Medical Specialties, PLLC Tacoma Washington 98405 —
West Virginia University Cancer Institute Morgantown West Virginia 26505 —
University of Wisconsin Carbone Cancer Center Madison Wisconsin 53792 —
Froedtert Hospital- Medical College of Wisconsin Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05468489, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 20, 2025 · Synced Sep 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05468489 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →